DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Intracranial Hemorrhage (ICH) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Intracranial Hemorrhage, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Intracranial Hemorrhage Market

• The market size for Intracranial Hemorrhage in the leading markets is expected to grow significantly by 2036.

• The United States accounted for the highest Intracranial Hemorrhage treatment market size in 7MM in 2025 compared with the EU4 countries, the United Kingdom, and Japan.

• DelveInsight’s analysis indicates that the total market size of Intracranial Hemorrhage in the 7MM is expected to increase substantially during the forecast period 2022–2036.

• In the US, the overall incidence of ICH is about 21.1 per 100,000, with a female incidence of 18.4 per 100,000 and a male incidence of 22.8 per 100,000.

• Data suggests that ICH accounts for approximately 10%–20% of all strokes, with incidence increasing significantly in individuals aged 55 years and older.

• Epidural hematomas are present in approximately 2% of head injury patients and account for 5% to 15% of fatal head injuries.

• The incidence of subdural hematoma is estimated to be between 5%–25% of patients with significant head injuries and is associated with an annual incidence of 1 to 5 cases per 100,000 population.

• Leading Intracranial Hemorrhage companies, such as Grace Therapeutics and others, are developing new ICH therapies that are expected to enter the market in the coming years.

• The promising Intracranial Hemorrhage therapies in development include GTx-104 (nimodipine) and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/intracranial-hemorrhage-epidemiology-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr

Key Factors Driving the Intracranial Hemorrhage Market

• Increasing Incidence in Aging Populations: The incidence of Intracranial Hemorrhage increases significantly with age, particularly among individuals aged 55 years and older. Aging populations, along with increasing prevalence of hypertension and anticoagulant use, are contributing to the growing patient burden globally.

• Growing Demand for Acute Neurocritical Care and Minimally Invasive Interventions: Management strategies involving rapid stabilization, minimally invasive surgical approaches, catheter-based interventions, and image-guided hematoma evacuation are gaining traction to improve patient outcomes and reduce neurological complications.

• Rising Use of Anticoagulation Reversal Agents and Supportive Therapies: Current pharmacologic approaches include anticoagulation reversal agents such as ANDEXXA/ONDEXXYA (andexanet alfa) and PRAXBIND (idarucizumab), alongside blood pressure control and neurocritical supportive care, contributing to expanding treatment utilization.

• Emerging Neuroprotective and Hemostatic Therapies: The development of therapies targeting vascular integrity, neuroinflammation, hematoma expansion, and neuroprotection is expected to transform the future ICH treatment landscape.

Intracranial Hemorrhage Competitive Landscape

• Several Intracranial Hemorrhage therapies in development include GTx-104 (Grace Therapeutics) and other investigational therapies focused on neuroprotection, hemostatic intervention, vascular stabilization, and minimally invasive treatment approaches.

• These therapies aim to improve tolerability, optimize drug delivery, reduce secondary brain injury, limit hematoma expansion, and improve survival and neurological outcomes compared with currently available supportive care approaches.

Discover more about therapies set to grab major Intracranial Hemorrhage market share @ Intracranial Hemorrhage Treatment Landscape

Recent Developments in the Intracranial Hemorrhage Market

• In February 2026, Balt reported that the US FDA granted premarket approval to its Squid liquid embolic agent for embolization of the middle meningeal artery as an adjunct to standard care in patients with large, symptomatic chronic subdural hematoma.

• In April 2026, Grace Therapeutics reported that results from its STRIVE-ON Phase III safety trial evaluating GTx-104 were accepted for presentation at the American Academy of Neurology Annual Meeting 2026.

• In March 2026, Grace Therapeutics announced that abstracts on unmet medical needs and potential benefits of GTx-104 were accepted for presentation at major medical conferences, including the Society of Critical Care Medicine Critical Care Congress 2026.

• In August 2025, the US FDA accepted the NDA for GTx-104 for formal review, assigning a PDUFA target date in April 2026.

• In June 2025, Grace Therapeutics submitted a New Drug Application (NDA) to the US FDA for GTx-104 based on positive Phase III STRIVE-ON trial data.

• In February 2025, Grace Therapeutics announced that its Phase III STRIVE-ON safety trial met its primary endpoint and demonstrated clinical benefit compared with orally administered nimodipine.

What is Intracranial Hemorrhage (ICH)?

Intracranial hemorrhage (ICH) refers to bleeding within the skull and is an important cause of stroke, disability, and mortality. ICH may occur spontaneously or following traumatic injury. Spontaneous ICH is associated with conditions such as hypertension, cerebral amyloid angiopathy, arteriovenous malformations, anticoagulation therapy, ruptured aneurysms, tumors, and venous sinus thrombosis.

Traumatic ICH can occur following head injury, particularly in individuals receiving anticoagulation therapy. Symptoms commonly include severe headache, vomiting, altered consciousness, focal neurological deficits, and neurological deterioration. Neuroimaging techniques such as CT scans and MRI play a critical role in diagnosis and subtype identification.

Intracranial Hemorrhage Epidemiology Segmentation

The Intracranial Hemorrhage epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The Intracranial Hemorrhage market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of Intracranial Hemorrhage

• Gender-specific Cases of Intracranial Hemorrhage

• Age-specific Cases of Intracranial Hemorrhage

• Type-specific Cases of Intracranial Hemorrhage

Scope of the Intracranial Hemorrhage Market Report

• Therapeutic Assessment: Intracranial Hemorrhage current marketed and emerging therapies

• Intracranial Hemorrhage Market Dynamics: Key Market Forecast Assumptions of Emerging Intracranial Hemorrhage Drugs and Market Outlook

• Key Companies: Grace Therapeutics and others

• Key Therapies: GTx-104 (nimodipine), ANDEXXA/ONDEXXYA (andexanet alfa), PRAXBIND (idarucizumab), and others

• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Intracranial Hemorrhage Market Access and Reimbursement

To know more about Intracranial Hemorrhage companies working in the treatment market, visit @ Intracranial Hemorrhage Clinical Trials and Therapeutic Assessment

Table of Contents

1. Intracranial Hemorrhage Market Report Introduction

2. Executive Summary for Intracranial Hemorrhage

3. SWOT Analysis of Intracranial Hemorrhage

4. Intracranial Hemorrhage Patient Share (%) Overview at a Glance

5. Intracranial Hemorrhage Market Overview at a Glance

6. Intracranial Hemorrhage Background and Overview

7. Intracranial Hemorrhage Epidemiology and Patient Population

8. Country-Specific Patient Population of Intracranial Hemorrhage

9. Intracranial Hemorrhage Current Treatment and Medical Practices

10. Intracranial Hemorrhage Unmet Needs

11. Intracranial Hemorrhage Emerging Therapies

12. Intracranial Hemorrhage Market Outlook

13. Country-Wise Intracranial Hemorrhage Market Analysis (2022–2036)

14. Intracranial Hemorrhage Market Access and Reimbursement of Therapies

15. Intracranial Hemorrhage Market Drivers

16. Intracranial Hemorrhage Market Barriers

17. Intracranial Hemorrhage Appendix

18. Intracranial Hemorrhage Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services